Drug Trial Radar · NCT06986811
CEB-01 in Pediatrics With Locally Resectable Abdominal Tumors
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
May 6, 2025
Primary completion
May 2029
Study completion May 2029
Sponsor
- Lead sponsor
- CEBIOTEXIndustry
- Sponsor type
- Industry
- Collaborators
- CEBIOTEX S.L.
- First posted
- May 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The CEB-01 implant is a membrane containing SN-38, the active metabolite of irinotecan, an already authorized chemotherapeutic agent. After surgical removal of the abdominal cancer tumor, CEB-01 will be placed in the surgical bed for a local and sustained release of the chemotherapy. This is expected to delay or prevent local recurrence of abdominal tumors after surgery, while keeping a tolerable toxicity profile. The study aims to assess the safety, tolerability, pharmacokinetics, and efficacy of CEB-01 in pediatric patients with locally resectable abdominal tumors including Soft Tissue Sarcoma (STS), high-risk Neuroblastoma (NB), Wilms tumor (WT), germ cell tumors (GCT), extracranial malignant rhabdoid tumor (eMRT), synovial sarcoma (SS), desmoplastic small round cell tumor (DSRCT) and fibrolamellar hepatocellular carcinoma (FL-HCC)
Conditions
- Locally Resectable Pediatrics Tumors
Interventions
Standard surgeryProcedure
The location and size of the tumor determine the type of surgery.
CEB-01Drug
It is novel formulation for local release of chemotherapy. It consists of a biocompatible and biodegradable nanofiber membrane made of poly(lactic-co-glycolic acid) (PLGA), which is loaded with the anti-tumor drug SN-38 and implanted in the surgical bed after tumor removal.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of Adverse Events (AEs) (Safety)Time frame: Through study completion, average 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital Sant Joan de Déu
Esplugues de Llobregat, Barcelona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.